🔎 Trials Near Me

Utama › Kanser Payudara Triple-Negatif › Louisiana

Kajian klinikal Kanser Payudara Triple-Negatif di Louisiana

6 kajian untuk Kanser Payudara Triple-Negatif sedang mencari peserta di lokasi di Louisiana.

Bandar di Louisiana

Teks kajian rasmi (Bahasa Inggeris)

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

  • CHRISTUS St. Frances Cabrini Hospital Center for Cancer Care ( Site 0109), Alexandria
  • Louisiana State University Health Sciences Shreveport ( Site 0029), Shreveport
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06393374

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

  • Ochsner Clinic Foundation ( Site 0021), New Orleans
  • Louisiana State University Health Sciences Shreveport ( Site 0053), Shreveport
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06966700

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  • Mary Bird Perkins Cancer Center, Baton Rouge
  • University Medical Center - New Orleans, New Orleans
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT05633654

A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors

  • LSU Health Sciences Center, Shreveport
Mengambil pesertaFasa awal 1
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Ogo 2025 · NCT06700070

CtDNA Based MRD Testing for NAC Monitoring in TNBC

  • Louisiana State University, New Orleans
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Wanita · Dikemas kini 7 Jan 2025 · NCT06230185

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.